Spots Global Cancer Trial Database for Combination Chemotherapy in Treating Patients With Advanced Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Combination Chemotherapy in Treating Patients With Advanced Cancer

Official Title: A Phase I Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) Administered Daily x 5 in Combination With Cisplatin

Study ID: NCT00024323

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

cisplatin

triapine

Study Description

Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining 3-AP with cisplatin in treating patients who have advanced cancer.

Detailed Description: OBJECTIVES: * Determine the maximum tolerated dose of cisplatin when administered with 3-AP in patients with advanced cancer. * Determine the toxic effects of this regimen in these patients. * Determine the antitumor responses in patients treated with this regimen. OUTLINE: This is a dose-escalation study of cisplatin. Patients receive 3-AP IV over 2 hours on days 1-4 and cisplatin IV over 1 hour on days 2 and 3. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of cisplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. PROJECTED ACCRUAL: A total of 15-25 patients will be accrued for this study.